Valuation: Adaptive Biotechnologies Corporation

Market Cap 4.15B 3.55B 3.32B 3.04B 5.71B 397B 5.79B 39.28B 15.32B 199B 15.57B 15.24B 659B P/E 2026 *
-47.7x
P/E 2027 * -147x
Enterprise Value 4.09B 3.5B 3.28B 3B 5.63B 391B 5.7B 38.72B 15.1B 197B 15.35B 15.02B 650B EV / Sales 2026 *
13.9x
EV / Sales 2027 * 11.3x
Free-Float
97.92%
Yield 2026 *
-
Yield 2027 * -
1 day+2.16%
1 week+5.05%
Current month+15.15%
1 month+18.41%
3 months+87.25%
6 months+70.99%
Current year+60.04%
1 week 23.92
Extreme 23.92
26.16
1 month 21.74
Extreme 21.74
26.16
Current year 12
Extreme 12
26.16
1 year 12
Extreme 12
26.16
3 years 2.28
Extreme 2.28
26.16
5 years 2.28
Extreme 2.28
40
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Executive Officer 51 08/09/2009
Director of Finance/CFO 42 08/04/2024
President 54 01/02/2018
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 01/02/2013
Director/Board Member 70 01/12/2013
Date Insider Type Main position Quantity % Market Cap.
18/08/26 Fiscal year

Director

60,664 0.0379%
18/08/26 Fiscal year

Chief Executive Officer

836,028 0.5224%
17/08/26 Fiscal year

Director

154,690 0.0967%
Change 5-day change 1-year change 3-year change Capi.($)
+2.16%+5.05%+99.92%+310.58% 4.15B
-7.79%+18.77%+208.18%+29.94% 3.76B
+1.24%+2.57%+36.48%+62.79% 3.4B
+3.45%+7.26%+274.79%+480.07% 2.51B
-3.61%+3.84%-21.05%-21.14% 2.41B
-0.88%+16.87%+27.81% - 1.48B
+4.22%+51.58%+252.65%-19.48% 1.29B
-2.40%-5.13%+16.63%+37.70% 1B
-2.72%-2.82%-36.30%+0.33% 552M
-3.35%-14.53%+8.12%+163.32% 537M
Average -0.97%+8.64%+86.73%+116.01% 2.11B
Weighted average by Cap. -0.84%+9.97%+110.38%+146.43%

Financials

2026 *2027 *
Net sales 293M 251M 235M 215M 404M 28.06B 409M 2.78B 1.08B 14.09B 1.1B 1.08B 46.62B 359M 307M 287M 263M 494M 34.3B 500M 3.4B 1.32B 17.23B 1.35B 1.32B 57B
Net income -85.78M -73.48M -68.75M -62.93M -118M -8.21B -120M -812M -317M -4.12B -322M -315M -13.64B -27.55M -23.6M -22.08M -20.21M -37.94M -2.64B -38.44M -261M -102M -1.32B -103M -101M -4.38B
Net Debt -58.99M -50.53M -47.28M -43.28M -81.23M -5.64B -82.3M -559M -218M -2.84B -222M -217M -9.38B -104M -88.94M -83.22M -76.18M -143M -9.93B -145M -983M -383M -4.99B -390M -381M -16.51B
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
21/08/26 $25.99 +2.16% 1,816,948
20/08/26 $25.44 -0.20% 1,966,210
19/08/26 $25.49 +3.79% 2,145,837
18/08/26 $24.56 -0.85% 1,878,377
17/08/26 $24.77 +0.12% 2,668,386
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
25.99USD
Average target price
25.07USD
Spread / Average Target
-3.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADPT Stock